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Abstract
Background: Prior microrheologic assessments of selected, microlitre plugs of cystic fibrosis (CF)
sputum suggest no intrinsic rheologic abnormality. However, such analyses may not be
representative of CF sputum as a whole. We therefore reassessed this question using whole
sputum macrorheology. Additionally, we wished to further explore the relationships between
sputum rheology, inflammation and infection.
Methods: Dynamic oscillatory macrorheometry was performed on whole expectorated sputum
from stable adults with CF (n = 18) and COPD (n = 12) and induced sputum from normal controls
(n = 7). Concomitant sputum inflammatory mediator levels were measured in CF and COPD
samples. Sputum collected from CF subjects (n = 6) at commencement and completion of
intravenous antibiotic therapy for an infective exacerbation was also assessed.
Results: CF sputum neutrophil elastase activity (NE) was significantly related to degree of sputum
purulence (p = 0.049) and correlated significantly with measures of sputum viscoelasticity (r =
0.696, p = 0.008 for storage modulus G' at 9 Hz). There were significant differences in
viscoelasticity between subject groups when samples were compared irrespective of appearance/
degree of sputum purulence. However, the macrorheology of mucoid CF sputum did not differ
from normal sputum (eg median (range) G' at 9 Hz 2.25 (0.79, 3.26) vs 2.04 (1.4,4.6) Pa, p = 1). In
contrast, mucoid COPD samples demonstrated significantly greater viscoelasticity (G' at 9 Hz 4.5
(2.4, 23) Pa) than sputum from both CF (p = 0.048) & normal subjects (p = 0.009). Antibiotic
therapy during exacerbations was associated with significant reductions in CF sputum
viscoelasticity, with mean (SD) G' at 9 Hz decreasing from 28.5 (11.5) Pa at commencement to 6.4
(4.6) Pa on day 7 (p = 0.01).
Conclusion: The macrorheologic properties of whole, mucoid CF sputum are not different from
normal, confirming the results of prior microrheologic studies. Instead, CF sputum viscoelasticity
is related to secondary infection, decreases with intravenous antibiotic therapy and correlates with
inflammation. In contrast, COPD sputum demonstrates inherently greater viscoelasticity, providing
a novel target for potential therapeutic interventions.
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Background
The exact pathophysiology linking cystic fibrosis trans-
membrane conductance regulator (CFTR) dysfunction
with CF pulmonary disease remains unclear, although the
popular airway surface liquid (ASL) volume theory [1,2]
predicts that dehydrated, thickened respiratory secretions
are integral to mucociliary stasis and the subsequent
development of CF airway pathology. Indeed, thickened,
tenacious respiratory secretions are a ubiquitous feature of
CF that are widely considered to represent dehydrated res-
piratory secretions with abnormal viscoelasticity [3-5].
However, prior investigations have failed to demonstrate
abnormal viscoelasticity of CF sputum when compared
with canine tracheal mucus [6]. While some prior studies
have not shown CF sputum to have greater viscoelasticity
than asthma, bronchiectasis and chronic bronchitis spu-
tum [7,8], others have shown significantly higher viscoe-
lasticity of CF than COPD sputum [9]. There are a number
of potential limitations of some previous investigations,
including the use of high shear rates that may disrupt the
mucus gel network of respiratory mucus [7,8], the com-
parison of CF sputum with non-human (canine) 'normal'
mucus [6] and the analysis of microlitre quantities of
selected sputum plugs that raise the possibility of sample
bias given the heterogeneity of CF sputum [6].
Simple visual inspection of CF sputum reveals its obvious,
marked heterogeneity. This visual variability is confirmed
in sputum measures including inflammatory markers [10]
and rheology, with work from our and other groups show-
ing large variations in viscoelasticity when analysing sep-
arate aliquots from the same sputum samples (coefficients
of variation of up to 150% for aliquots from the same
samples) [11,12]. This extreme variability must create
concern over the validity of analyses that use small
selected sputum portions.
In the context of these validity concerns, the disparity
between current concepts around the pathogenesis of CF
lung disease and its expression in the form of sputum rhe-
ology led us to re-examine the rheology of CF sputum
using whole sputum samples to reduce the risks of sample
bias and improve reproducibility. We hypothesised that
macrorheologic analysis of whole CF sputum, when com-
pared to normal human sputum (obtained by induction),
would enable the postulated intrinsic rheologic abnor-
malities of CF sputum to be demonstrated. Additionally,
we further investigated the contribution of infection to the
rheology of CF sputum from individual subjects by evalu-
ating the effects of intravenous antibiotic therapy upon
sputum rheology. Finally, relationships between sputum
inflammatory markers and sputum rheology were investi-
gated.
Methods
Subjects and Study Design
This was a prospective study comprising firstly a cross-sec-
tional component in which COPD and CF subjects pro-
duced a single spontaneously expectorated sputum
sample, while normal subjects produced a single sputum
specimen following sputum induction (SI) with 4.5%
hypertonic saline. A prospective, open interventional
component involved analysing sputum samples from CF
subjects at the commencement of a course of intravenous
antibiotic therapy for an infective exacerbation, and then
during and at the completion of the course. The local
regional ethics committee provided approval.
All subjects were recruited through the Respiratory Medicine
Department of Southampton General Hospital, were current
non-smokers over 16 years of age, and provided informed
consent. No subject was prescribed mucolytic agents or sys-
temic corticosteroids, and 'stable' subjects had not received
supplemental antibiotic therapy in the prior two weeks. Nor-
mal subjects (n = 7) were healthy volunteers without respira-
tory disease, mean (SD) age 31 (7.6) years. Twelve chronic
bronchitic COPD subjects, 72 (11) years old and FEV1 57.2
(33.9)% predicted, had a history of chronic daily sputum
production and were clinically stable with no recent exacer-
bation of lung disease. These subjects had a significant ciga-
rette smoking history (at least 20 pack years) and irreversible
airflow obstruction (FEV: FVC<0.7). Sputum was obtained
from 18 clinically stable, adult CF subjects (diagnosed by
standard criteria) with chronic pulmonary Pseudomonas aeru-
ginosa infection, age 24.9 (7.4) years and FEV1 46.6 (13.9)%
predicted. For the investigation of the effects of intravenous
antibiotic therapy, six CF subjects receiving intravenous anti-
biotic therapy for an infective exacerbation were included
(meeting predefined criteria incorporating ³ 10% fall in FEV1
from baseline in combination with at least two of the follow-
ing: 1. Increased sputum purulence; 2. Increased sputum vol-
ume; 3. Fevers or systemic symptoms; 4. Weight loss of at
least 1 kg; 5. New crackles on chest auscultation; 6. New infil-
trates on chest radiograph.).
Specimens were collected in sterile, hermetically sealed
containers and frozen at -80°C (previous work and our
own unpublished data has shown no significant effect of
freezing upon the rheological properties of sputum ana-
lysed after a single freeze-thaw cycle [13]) and were char-
acterised according to macroscopic appearance, as
mucoid (no evidence of pus), purulent (uniformly puru-
lent whether green or yellow) or mucopurulent (mixed
mucoid & purulent components) [6,8].
SI was performed according to the standardised protocol
of the European Respiratory Society taskforce [14] using
an ultrasonic nebuliser (Devilbiss, Somerset, USA).Respiratory Research 2009, 10:63 http://respiratory-research.com/content/10/1/63
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Rheologic Analysis
Sputum was thawed at room temperature for one hour
and salivary contamination carefully removed. The whole
sample was then gently homogenised with 10 strokes in a
5 mL syringe. High shear forces can disrupt mucus gel
structure and influence measured rheology and prior
investigators have reported that homogenization may
destroy mucus structure [15]. However, those reports
employed vigorous homogenisation including "blending
by vigorous stirring for six minutes" [15] in contrast to the
gentle homogenisation technique used in the current
studies. Our group has recently shown that this homoge-
nisation procedure has no effect upon sputum pore size
[16] and that there was no significant difference between
the rheological characteristics of the gently homogenised
sputum specimens and selected nonhomogenised aliq-
uots from the same sputum samples [11]. Rheology was
performed using a Carri-Med CSL 100 controlled-stress
rheometer (Carri-Med Ltd, Dorking, England) operating
in dynamic oscillatory mode employing a 4 cm stainless
steel parallel-plate geometry. Following homogenisation,
the sample was loaded in the rheometer geometry and any
entrapped air bubbles removed. A solvent trap containing
distilled water was used to prevent dessication and analy-
ses were performed at 20°C to reduce enzymatic sample
degradation. Samples equilibrated for 30 minutes prior to
all experiments to enable relaxation to their original gel
structure. Torque sweeps were performed initially (0.1 –
10 Pa) to determine a stress at which the response of the
elastic modulus (G') and loss modulus (G'') was within
the linear viscoelastic region for the sample. Logarithmic
frequency sweeps (0.1–10 Hz) were then performed in
triplicate at the determined shear stress and displacement.
Data obtained from these experiments were used to calcu-
late rheologic parameters within the linear viscoelastic
region, with particular interest in storage modulus G', and
dynamic viscosity h ', at the frequencies 0.3 Hz and 9 Hz.
This provided both high and low frequency data, with 9
Hz approximating to ciliary beat frequency.
Determination of Sputum Inflammatory Markers
Thirteen CF and seven COPD sputum samples had con-
comitant inflammatory mediator levels determined. After
thawing the samples on ice, salivary contamination was
removed by pipette and the sample diluted (1:1 mL per g)
with phosphate buffered saline (PBS, Gibco, UK) for sol-
ubilisation of mediators. The samples were thoroughly
mixed (vortex mixer for five minutes then orbital plate
mixer for 20 minutes, on ice) then centrifuged at 20,000
g, at 4°C for 20 minutes. The supernatant was aspirated
and used to determine neutrophil elastase (NE) activity,
IL-8, myeloperoxidase (MPO) and terminal complement
complex (TCC) levels. Commercially available enzyme-
linked immunosorbent assay (ELISA) kits were used to
measure total IL-8 (Pelikine compact, Mast Diagnostics,
Liverpool, UK) in supernatant samples diluted at either
1:1000 or 1:10000 with assay dilution buffer, and TCC
(Quidel, California, USA) in supernatant samples diluted
1:2 with assay diluent. MPO was measured using a com-
mercially available radioimmunoassay kit (Pharmacia,
Uppsala, Sweden) in supernatant samples diluted at
1:1000 with PBS. NE activity was measured in samples
diluted 1:10 with assay buffer as previously described
[17].
Data Analysis
The one-sample Kolmogorov-Smirnov Test indicated that
rheological parameters assessed in normal and COPD
samples were normally distributed. However, for CF sam-
ples, a number of parameters were not normally distrib-
uted and non-parametric tests were therefore used for
comparisons. The Kruskal-Wallis test for multiple inde-
pendent samples was used to evaluate differences between
the groups, and Mann Whitney U test to compare groups
individually. Correlations between variables used Spear-
man's test for non-normally distributed variables. For
serial studies of the same subjects, parametric analyses
were used. P values less than 0.05 were considered signif-
icant. Where large numbers of outcome measures were
assessed, a Bonferroni adjustment has been employed such
that significance at the 5% level was indicated for p values
< 0.05/m where m is the number of comparisons made.
SPSS for Windows release 11.0.0 (SPSS Inc, Chicago) was
used.
Results
CF Sputum Purulence and Sputum Macrorheology
As expected, CF sputum inflammatory mediator levels
were positively related to the degree of purulence assessed
macroscopically (e.g. median NE levels increased signifi-
cantly from 2.75 mu/ml for mucoid to 13.85 for mucopu-
rulent and 31.95 for purulent, p = 0.049 by Kruskal-
Wallis; see Table 1), consistent with the prior findings of
Stockley  et al in subjects with chronic bronchitis and
bronchiectasis [18]. Significant differences in sputum rhe-
ology were also seen between CF sputum samples, for all
measures of viscoelasticity (G' and h ' at both 0.3 and 9 Hz,
Log G* at 1 rad s-1 and Tan d), according to the degree of
sputum purulence (see Figure 1 for indication).
Relationship Between CF Sputum Inflammatory Mediators 
and Macrorheology
There were significant positive correlations with sputum
viscoelasticity measures for NE activity (r = 0.696, p =
0.008 for G' at 9 Hz; r = 0.735, p = 0.004 for h ' at 9 Hz),
MPO (r = 0.741, p = 0.006 for G' at 9 Hz; r = 0.72, p =
0.008 for h ' at 9 Hz) and TCC (r = 0.631, p = 0.028 for G'
at 9 Hz; r = 0.653, p = 0.021 for h ' at 9 Hz) but no signifi-
cant relationships for IL-8. These relationships extendRespiratory Research 2009, 10:63 http://respiratory-research.com/content/10/1/63
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prior data showing correlations between CF sputum infec-
tion and cough transportability [19] and between CF spu-
tum inflammation and sputum transportability [20].
Comparison Between Patient Groups
There were large, statistically significant differences seen
between normal, COPD and CF sputum when sputum
was compared between groups irrespective of sputum
appearance/degree of sputum purulence (p £  0.01 by
Kruskal-Wallis Test for all analysed rheological parame-
ters, G' and h ' at both 0.3 and 9 Hz, Log G* @ 1 rad s-1 and
Tan d; Figure 2 provides indication of the magnitude of
the differences, for dynamic viscosity).
When analyses were restricted to macroscopically similar,
mucoid ('uninfected') sputum, there were no differences
in rheology between CF (mean percent predicted FEV1
52.5%) and normal sputum. Mucoid COPD sputum
showed higher values than both CF and normal sputum
for all parameters of viscosity and elasticity (see Table 2
and Figure 3 for an indication of the magnitude of differ-
ences).
For the COPD samples levels of inflammatory mediators
were mostly undetectable in these mucoid samples
(median [range] neutrophil elastase levels for mucoid
samples 0 [0–1.3] mu/ml), once again confirming the low
levels of inflammation present in COPD sputum of
mucoid macroscopic appearance [18]. Not surprisingly
therefore, no relationships were seen between sputum
Table 1: Inflammatory mediator levels in sputum from CF and COPD subjects.
Cystic fibrosis
NE (mu/ml) IL-8 (X102 ng/mL) TCC (ng/mL) MPO (mg/L)
Mucoid (n = 1) 2.75 0.85 0 34.30
Mucopurulent (n = 6) 13.85 (8.31–42.89) 1.22 (0.89–3.94) 0 (0–0.73) 53.47 (39.13–213.35)
Purulent (n = 6) 31.95 (14.94–62.13) 2.11 (0.91–34.35) 30.36 (0–326.44) 139.41 (51.44–238.15)
P value * 0.049 0.141 0.089 0.169
COPD
Mucoid (n = 4) 0 (0–1.33) 6.52 (3.51–8.14)
Mucopurulent (n = 2) 4.5 (0–9) 9.77 (5.93–13.6)
Purulent (n = 1) 35.11 6.15
P value * 0.20 0.85
(Values presented are median (range). NE – neutrophil elastase activity, IL-8 – interleukin-8, TCC – terminal complement complex, MPO – 
myeloperoxidase. * by Kruskal-Wallis Test).
Box and whisker plot comparing mucoid, mucopurulent and  purulent sputum from CF subjects for storage modulus Figure 1
Box and whisker plot comparing mucoid, mucopuru-
lent and purulent sputum from CF subjects for stor-
age modulus. (Illustrating the graded increase in elasticity 
measures at 9 Hz occurring with increasing macroscopic 
purulence of sputum from stable CF subjects. Mucoid n = 4, 
mucopurulent n = 10, purulent n = 8. * by Mann-Whitney U-
test).Respiratory Research 2009, 10:63 http://respiratory-research.com/content/10/1/63
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inflammatory mediators and viscoelasticity for COPD
samples.
Effect of intravenous antibiotic therapy upon sputum 
rheology
Two subjects were only able to provide sputum at com-
mencement of the study and were therefore excluded
from subsequent analysis. Mean FEV1 for the remaining
subjects was 43%. There were significant decreases from
day 0 to day 7 in several rheologic parameters including
storage modulus G' at both 0.3 Hz (p = 0.006) and 9 Hz
(p = 0.01; see Figure 4). It may be appropriate to incorpo-
rate a Bonferroni adjustment into these analyses, in which
case significance at the 5% level is indicated by a p value
of 0.01 (0.5/5).
Discussion
The current observations extend prior data that have
shown relationships between CF sputum bacteriology and
cough transportability [19] and between CF sputum
inflammatory mediators and mucus transportability [20].
To our knowledge, the current data are the first to demon-
strate direct positive relationships between CF sputum
inflammatory mediator levels and sputum viscoelasticity.
Furthermore, consistent with the importance of puru-
lence/infection in determining the magnitude of sputum
viscoelasticity in CF subjects, applying an effective anti-
infective therapy (intravenous antibiotics) was associated
with large reductions in sputum elasticity. The original
primary hypothesis of this study was that our alternative,
large volume, whole sputum technique would allow us to
prove differences between CF and normal sputum rheol-
ogy by attenuating the variability associated with selected
sputum plugs. However, our data using macrorheologic
analysis support the findings of prior microrheologic
analyses [6] that rheologic abnormalities of CF sputum
are acquired in relation to infection/inflammation rather
than being intrinsic.
Other recent lines of evidence accord with our data sug-
gesting that rheologic abnormalities of CF sputum are sec-
ondary abnormalities due to established infection and
inflammation. For example, if respiratory mucus were
inherently abnormal in CF, nasal mucociliary clearance
would be impaired in CF children before the onset of sig-
Table 2: Macrorheologic characteristics of mucoid sputum from CF, COPD and normal subjects.
CF (n = 4) Normal (n = 7) COPD (n = 8)  P value *
(CF v COPD)
P value *
(N v COPD)
G' @ 0.3 Hz (Pa) 0.54 (0.03–1.1) 0.39 (0.02–1.6) 1.4 (0.22–13.8) 0.109 0.054
G' @ 9 Hz (Pa) 2.25 (0.79–3.26) 2.04 (1.4–4.6) 4.5 (2.4–23) 0.048 0.009
h ' @ 0.3 Hz (Pa) 0.24 (0.04–0.38) 0.15 (0.04–0.49) 0.41 (0.16–1.8) 0.154 0.04
h ' @ 9 Hz (Pa) 0.03 (0.02–0.04) 0.025 (0.023–0.034) 0.04 (0.025–0.1) 0.109 0.002
Log G* (1) 0.89 (-0.08–1.2) 0.76 (-0.06–1.3) 1.3 (0.7–2.2) 0.073 0.023
Tan d (1) 0.87 (0.65–2.6) 0.93 (0.43–2.5) 0.55 (0.2–1.6) 0.214 0.094
(No significant differences between CF and normal sputum, p > 0.68 for all measures. Values presented are median (range). (1) -- @ 1 Rad s-1, G' – 
storage modulus, h ' – dynamic viscosity, tan d – loss tangent, Log G* – mucus rigidity index. Log G* & Tan d are dimensionless. * by Mann-Whitney 
U-test).
Box and whisker plot comparing rheology of sputum (irre- spective of macroscopic appearance) from normal, COPD  and CF subjects, for dynamic viscosity Figure 2
Box and whisker plot comparing rheology of sputum 
(irrespective of macroscopic appearance) from nor-
mal, COPD and CF subjects, for dynamic viscosity. 
(As indicated, significant differences were observed between 
all groups for dynamic viscosity h ' at 0.3 Hz. Normal n = 7, 
COPD n = 12, CF n = 18. * by Mann-Whitney U Test).Respiratory Research 2009, 10:63 http://respiratory-research.com/content/10/1/63
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nificant sinonasal disease, however recent data refute this
[21]. Additionally, Bush et al recently showed no differ-
ences in sputum rheology between subjects with CF and
those with primary ciliary dyskinesia, suggesting the
importance of common secondary (infection, etc) rather
than primary events in the development of abnormal spu-
tum properties [22].
The current data therefore do not support the notion that
rheologically abnormal, dehydrated CF sputum (develop-
ing as a result of ASL volume loss) is the initial determi-
nant of the mucociliary stasis that is subsequently
associated with bacterial infection and progressive airways
obstruction in CF. Our data are more consistent with alter-
native primary models of CF pathophysiology, such as
those implicating excessive inflammation [23] or abnor-
mal susceptibility to respiratory infection [24,25], includ-
ing the recently described oxidative antimicrobial system
that appears inactive in the CF airway [26].
The current analysis, using dynamic oscillatory rheome-
try, did confirm significant intrinsic rheologic abnormali-
ties of non-infected sputum from chronic bronchitic
COPD subjects. The increased viscoelasticity of uninfected
COPD sputum is likely to be related to increases in mucin
concentration within COPD airway secretions [27] associ-
ated with goblet cell hypertrophy and submucosal gland
hyperplasia [28]. The recent demonstration of increased
quantities of mucins within COPD sputum (and signifi-
cant reductions in the amount of MUC5B and MUC5AC
Box and whisker plot comparing rheology of mucoid sputum  from normal, COPD and CF subjects for storage modulus Figure 3
Box and whisker plot comparing rheology of mucoid 
sputum from normal, COPD and CF subjects for 
storage modulus. (No significant differences were 
observed between normal and CF sputum for storage modu-
lus G' at 9 Hz. Normal n = 7, CF n = 4, COPD n = 8. * by 
Mann-Whitney U Test).
Change in CF sputum rheology with therapy for an infective exacerbation (Change in mean storage modulus G' at 9 Hz is  depicted Figure 4
Change in CF sputum rheology with therapy for an infective exacerbation (Change in mean storage modulus 
G' at 9 Hz is depicted. Error bars indicate SEM. * p = 0.01 for the comparison with day 0 by paired T-test; Using a Bonfer-
roni adjustment, significance at the 5% level is indicated by a p value of 0.01).Respiratory Research 2009, 10:63 http://respiratory-research.com/content/10/1/63
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in CF sputum) provides further evidence to support this
[29]. It is likely, therefore, that future effective mucolytic
agents in COPD will need to either solubilise (or dilute)
mucins in the airways or reduce mucin production from
airway epithelia. Macrolide antibiotics may represent a
potentially effective therapeutic option, with in vitro and
animal data demonstrating the ability of these agents to
attenuate mucin synthesis and mucus secretion [30,31] –
the effect of macrolides upon the macrorheology of spu-
tum from chronic bronchitic subjects requires further
evaluation.
A number of potential limitations of this study need con-
sideration. Firstly, our comparison of non-purulent respi-
ratory secretions relies upon a small number of CF
samples. Few CF subjects produce mucoid secretions, and
this created substantial difficulties in collecting such sam-
ples. Furthermore, it could be argued that those who pro-
duce mucoid secretions are likely to have milder disease
(and milder genotypes), however these subjects had a
mean percent-predicted FEV1 of only 52.5%. Furthermore,
we found no relationships between FEV1 and any sputum
rheological parameter when analysing the full CF data set
(consistent with prior work) [14] and there was no differ-
ence in sputum rheology between those CF subjects with
FEV1 < 50% predicted and those with FEV1 ³ 50% pre-
dicted (data not shown). Secondly, the sputum induction
(SI) process may have influenced the rheology of normal
sputum in vivo, given that the in vitro incubation of spu-
tum with hypertonic saline for 30 minutes has been
shown to reduce the mucus rigidity index [32]. However,
if SI had resulted in any significant reduction in sputum
viscoelasticity, this would be likely to have increased the
difference between CF and normal sputum, thereby
strengthening our finding of no difference. One recent
study showed no significant effect of SI upon the rheology
of respiratory mucus from non-expectorating normal sub-
jects although did provide data suggesting that SI alters
other physical properties of sputum [33]; however, find-
ings from this study are predicated on the assumption that
analysis of 'normal' respiratory secretions collected
directly from endotracheal tubes at surgery is the 'gold
standard' for normal human respiratory mucus.
Others have attempted to overcome some of the problems
that are inherent in collecting and evaluating clinical spec-
imens from subjects with and without respiratory disease
by evaluating the rheology of secretions obtained from
models of the CF airway. Baconnais et al found no differ-
ences in ion composition or viscosity between airway liq-
uid from normal and CF fetal tracheal xenografts [34].
In summary, using an alternative whole sputum macror-
heologic technique, these results confirm that COPD spu-
tum manifests inherent increases in viscoelasticity while
there is no inherent rheological abnormality of CF spu-
tum. Rather, CF sputum purulence (related to secondary
infection and inflammation) dominates abnormalities of
sputum rheology, and intravenous antibiotic therapy
improves these parameters. The early initiation in CF sub-
jects of therapies to limit the development of chronic bac-
terial infection and inflammation, are likely to be critical
for attenuating the development of rheologically altered
secretions and their later downstream effects on CF airway
function. In contrast, stable COPD subjects with chronic
sputum production are unlikely to derive rheologic bene-
fit from standard anti-inflammatory or anti-infective ther-
apies and efforts to develop therapies that solubilise
mucins or reduce mucin production from airway epithelia
require further evaluation. Macrolide antibiotics may
therefore offer attractive therapeutic potential in chronic
bronchitic COPD subjects.
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